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Letters
In Response:
Re: Ha¨gg O, Fritzell P. Letter. Spine 2003; 29:
1160–1.
Ha¨gg and Fritzell correctly commented that our study
had a small sample size.1,2 We discussed this in our orig-
inal publication.1 Also, Ha¨gg and Fritzell correctly com-
mented that estimated standard deviation in our study
was much larger than postulated in the preliminary cal-
culation of study size. Consequently, we underestimated
the sample size.
Power is important when a clinically relevant
difference is not statistically significant
Statistical power calculations can be valuable in plan-
ning an experiment. Leading statisticians do not recom-
mend postexperiment power calculations as a guide to
interpreting tests with statistically nonsignificant re-
sults.3 In other words, the postexperimental calculations
made by Ha¨gg and Fritzell are not recommended.2 Their
attempt of reducing the observed difference of minimal
clinical difference to tossing a coin is simply not valid.
Higher observed power does not imply stronger evi-
dence for a null hypothesis that is not rejected. It is point-
less to perform power calculations for hypotheses out-
side of the confidence interval because the data have
already told us that these are unlikely values.3 We know
that values inside the confidence interval are not refuted
by the data. According to a recent publication in Spine,
type II error occurs when a study fails to detect a prede-
termined magnitude of difference between treatments.4
In our study, the observed difference of 2.3 may well be
the accurate estimate and is much less than the predeter-
mined difference of 10 that the study was designed to
detect. As discussed in our article, the upper limit of the
confidence interval means that we cannot refute the pre-
determined difference; it is just less likely to occur.
The first and most essential step in the design of any
study is to clearly state the primary question or purpose.
We clearly defined the primary outcome to determine the
sample size and for proper statistical analysis. Ha¨gg and
Fritzell commented that an Oswestry Disability Index of
10 is probably a minimum to be clinically important.2 In
the study populations comprising the Swedish and the
Norwegian study, the measurement error was estimated
to 12.5,9 This means that the observed difference of 2.3 in
our study has no clinical relevance.
The sample mean is the best indicator of the
population value
The lack of precision is reflected in the wide confi-
dence interval (6.7–11.4), which includes the differ-
ence that we considered clinically relevant. Regardless of
the width of the confidence interval, the best indicator of
the population value is the sample estimate of 2.3. Ha¨gg
and Fritzell calculated that 80% power in our study re-
quires a doubled sample size.2 It is possible to double the
sample size in our study. The Swedish study included
patients who had been previously operated for disc her-
niation, whereas we designed 2 separate studies. The
second study was presented at the European League against
Rheumatism in Lisbon in 2003, but has not yet been pub-
lished.6 The mean difference was3.7 (13.5–6.2). Thus,
by mixing, the observed difference had been close to zero
and the confidence interval had been smaller.
A 25% difference in treatment response is considered
a medium relative difference.4 The difference in improve-
ment in our study was 17%, although the difference was
not clinically significant. Percentages, therefore, may be
misleading. When surgery is compared with nonsurgical
treatment, differences need to be clinically significant.
The correct price is what the marked is willing to pay.
We apologize for making incorrect referrals to the Swed-
ish study. Costs were presented at a conference in Nor-
way in 2001 but have not published until recently.7 Frit-
zell et al. estimated hospital costs (1999 currency) within
Swedish Public Health Care at 112,000 Swedish kroner
or $14,500 US. The estimated costs are much less than
the marked is willing to pay. In 2002, a populistic polit-
ical decision approved 1 billion Norwegian kroner or
$149 million US to give patients on a waiting list for
surgery in Norway an operation abroad. A large number
of lumbar fusions were performed at private spine cen-
ters in Sweden at an average prize of approximately
300,000 Norwegian kroner or $44,500 US. To our
knowledge, prices for lumbar fusion in California exceed
the price at Swedish private centers.
Fritzell et al. made a sensitivity analysis to show that
surgery are more cost-effective if costs for rehabilitation
is higher than observed, and if costs for the operation and
family support is lower.7 We agree that the marked price
for nonoperative treatment may be higher if the marked
believe that such treatment is as effective as surgery for
chronic low back pain. In our opinion, Fritzell et al.
underestimate the price for lumbar fusion in the current
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health marked in Western societies. The cost for family
support was based on retrospectively collected data. A
questionnaire was sent to the patients after the 2-year
follow up, probably several years after, but this is not
reported in their article.7 Based on this information,
costs for noninstrumented and instrumented fusion is no
longer significantly different. The validity of the retro-
spective telephone interviews and questionnaires are not
discussed in their paper. The Swedish study is supported
by the industry.
Was the difference in the Swedish study clinically
significant?
The main difference between the Swedish and the
Norwegian study is the improvement in the nonsurgical
group. The improvements in ODI after surgery are com-
parable in the 2 studies, 15.6 in the Norwegian study and
11.6 (at 2 years) in the Swedish study. The improvement
after nonsurgical treatment is 12.3 in the Norwegian
study and 2.8 in the Swedish study. The difference be-
tween treatments in the Swedish study is 8.8, which is
less than the measurement error. This means that despite
a P value of 0.001, the clinical relevance of the difference
is questionable.
Knowledge about the behavioral therapy approach in
exercises was available in Sweden when the Swedish
study was started. This approach was better compared
with control subjects, which were treated by their gen-
eral practitioners and given analgesics and unspecified
physiotherapy in a randomized Swedish study published
in 1992.8 The Swedish Lumbar Spine Study Group
should have acknowledged these results to offer the best
nonsurgical treatment.
Despite the limitation of the Norwegian and the
Swedish studies, we believe that both studies have con-
tributed more to the evaluation of the clinical efficacy of
lumbar fusion than previously published studies. We are
waiting for the publication of a randomized, controlled
trial that combines the advantages of the Norwegian and
the Swedish study.
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